Key result
Dahuang Zhechong pills linked to ~36% lower Th17/Treg ratio and improved inflammatory profiles in NAFLD.
Why the study?
NAFLD is linked to lipid peroxidation, inflammatory imbalance, and immune disorder, prompting investigation into inflammatory cytokines, adipocytokines, and Th17/Treg balance following Dahuang Zhechong pill treatment.
Does Dahuang Zhechong pills improve inflammatory cytokines, adipocytokines, and Th17/Treg balance in patients with nonalcoholic fatty liver disease?
Does Dahuang Zhechong pills improve inflammatory cytokines, adipocytokines, and Th17/Treg balance in patients with nonalcoholic fatty liver disease?
Absolute Event Rate: 1.52% vs 2.39%
p-value: p=<0.05
Administration of Dahuang Zhechong pills in NAFLD patients may regulate immune function by improving Th17/Treg balance and modulating inflammatory and adipocytokine levels.
Objectives. The occurrence and development of nonalcoholic fatty liver disease (NAFLD) is related to lipid peroxidation, imbalance of inflammatory response factors, and immune function disorder. This study was conducted with the purpose of investigating the expression levels of inflammatory cytokines and adipocytokines and Th17/Treg balance in NAFLD patients treated with Dahuang Zhechong pills (DHZCPs). Methods. The study recruited 100 NAFLD patients who were then arranged into the test group and control group. Patients in the test group were treated with DHZCPs, while patients in the control group were untreated. Peripheral TH17 and Treg cells were detected by flow cytometry, and peripheral IL-17, IL-10, hs-CRP, and TNF-α expression levels were determined by enzyme-linked immunosorbent assay (ELISA) methods. The concentrations of ghrelin, leptin, and adiponectin were quantitatively examined. Results. The levels of TC, TG, ALT, and AST were declined but the level of HDL-C was increased in NAFLD patients treated with DHZCPs compared with untreated patients ( P < 0.05 ). The ratio of Th17/Treg in NAFLD patients treated with DHZCPs was (1.52 ± 0.21), which was significantly lower than (2.39 ± 0.45) of untreated patients ( P < 0.05 ). The levels of IL-17, hs-CRP, and TNF-α were lower, but the level of IL-10 was higher in NAFLD patients treated with DHZCPs than that in untreated patients ( P < 0.05 ). The expression levels of ghrelin and adiponectin in NAFLD patients treated with DHZCPs were evidently higher than those in untreated patients ( P < 0.01 ), and the expression level of leptin in NAFLD patients treated with DHZCPs was evidently lower than that in untreated patients ( P < 0.01 ). Conclusions. Administration of DHZCPs regulates the immune function of NAFLD patients by keeping Th17/Treg balance and affecting the levels of inflammatory cytokines and adipocytokines.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2022) studied Nonalcoholic Fatty Liver Disease (NAFLD) (n=100). Dahuang Zhechong pills (DHZCPs) vs. Untreated was evaluated on Th17/Treg ratio (p=<0.05). Treatment with Dahuang Zhechong pills significantly reduced the Th17/Treg ratio (1.52 vs 2.39, P<0.05) and improved inflammatory and adipocytokine profiles in patients with NAFLD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: